Delcath Systems (DCTH) CEO Michel acquired 16,666 shares at $6.00

Insider transactions reported

Gerard J Michel (Chief Executive Officer at Delcath Systems Inc., DCTH) reported that they acquired 16,666 shares at $6.00 on Oct 22, 2024. After these transactions the filing shows 319,334 shares held directly.

Reporting person

Michel Gerard J

Role

CHIEF EXECUTIVE OFFICER

Options and other derivatives

Holdings before and after

• Common Stock: 302,668 to 319,334 direct
• Tranche B Warrants to Purchase Common Stock: 16,666 to 0 direct

Footnotes from the filing

1. 1. Immediately exercisable.
2. 2. The Tranche B Warrants expire the earlier of (i) twenty-one (21) days following the date of the Issuer's public announcement of record at least $10,000,000 in quarterly U.S. revenue from the commercialization of HEPZATO and (ii) March 31, 2026, provided, however, if the FDA Approval occurs on or before February 15, 2024 and the Tranche A Warrants have not been exercised in full on or before March 7, 2024, then the Tranche B Warrants shall automatically expire on March 8, 2024. The Issuer announced on October 17, 2024 that it had recorded at least $10,000,000 in quarterly U.S. revenue from the commercialization of HEPZATO and therefore such Tranche B Warrants expire on November 7, 2024.
3. 3. The Tranche B Warrants were acquired in the issuer's private placement of common stock and warrants and issued as part of a unit with common stock and Tranche A Warrants. The per unit purchase price was $5.09, including a purchase price of $4.84 per share of common stock and $0.125 for each of the Tranche A and Tranche B Warrants. Each unit consisted of one share of common stock and an accompanying common stock warrant valued at 140% of the aggregate purchase price (the Tranche A Warrant) and an accompanying common stock warrant valued at 100% of the aggregate purchase price (the Tranche B Warrant).

Transaction codes in this filing

Exercise or conversion of a derivative:

Code M marks the exercise or conversion of an option or other derivative under an exempt plan.

FAQ